Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

162.29 -2.74 (-1.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 371,891
Open 162.01
Bid (Size) 147.00 (3)
Ask (Size) 162.94 (1)
Prev. Close 165.03
Today's Range 159.97 - 167.89
52wk Range 118.18 - 426.56
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 Penny Stocks That Could Triple in 2022
Penny stocks are affordable and some with credible business models in all likelihood have the potential to generate superior returns. 
Via InvestorPlace
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
From BeiGene
Via Business Wire

Performance

YTD
-39.79%
-39.79%
1 Month
+18.27%
+18.27%
3 Month
-21.22%
-21.22%
6 Month
-37.79%
-37.79%
1 Year
-54.55%
-54.55%

More News

Read More
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
Via Benzinga
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
From BeiGene
Via Business Wire
Where BeiGene Stands With Analysts
Via Benzinga
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
From BeiGene
Via Business Wire
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
From BeiGene
Via Business Wire
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
From BeiGene
Via Business Wire
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
From BeiGene
Via Business Wire
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
From BeiGene
Via Business Wire
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
From BeiGene, Ltd.
Via Business Wire
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Via Benzinga
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
From BeiGene
Via Business Wire
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
Via Investor's Business Daily
34 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
99 Biggest Movers From Yesterday
Via Benzinga
52 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
Via Talk Markets
HFCAA News: 128 Chinese Stocks the SEC Could Delist
Via InvestorPlace
Recap: BeiGene Q1 Earnings
Via Benzinga
BeiGene Reports First Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
From BeiGene
Via Business Wire
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
From BeiGene
Via Business Wire
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
From BeiGene
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.